Pathogenesis, diagnosis and treatment of neuromyelitis optica: Changing concept of an old disease

Clinical and Experimental Neuroimmunology

Volumn 1, Issue 3, 2010, Pages 103-123

  Illes, Zsolt ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Aquaporin 4; Devic's disease; Neuromyelitis optica; Optic neuritis; Transverse myelitis

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

AUTOIMMUNITY; B CELL LYMPHOMA; DISEASE COURSE; GENETIC ASSOCIATION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RELAPSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 79952053960     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/j.1759-1961.2010.00011.x     Document Type: Review

References (179)

1. Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet. 1870; 1: 76-8.
2. Devic E. Myelite subaiguë compliquée de névrite optique. Bull Med. 1894; 8: 1033-4.
3. Gault F. De la neuromyélite optique aiguë. Thése. Lyon, France, 1894.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-12. (Pubitemid 39626806)
5. Lehmann GL, Gradilone SA, Marinelli RA. Aquaporin water channels in central nervous system. Curr Neurovasc Res. 2004; 1: 293-303.
6. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130: 1235-43. (Pubitemid 47355956)
7. Magana SM, Pittock SJ, Lenneon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol. 2009; 66: 964-6.
8. Tait MJ, Saadoun S, Bell BA, Papdopoulos MC. Water movements in the brain: the role of aquaporins. Trends Neurosci. 2008; 31: 37-43.
9. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin4. J Neuroinflammation. 2008; 5: 22. doi: 10.1186/1742-2094-5-22.
10. Frigeri A, Gropper MA, Turck CV, et al. Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes. Proc Natl Acad Sci U S A. 1995; 92: 4328-31.
11. Frigeri A, Gropper MA, Umenishi F, et al. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci. 1995; 108: 2993-3002.
12. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 80: 575-7.
13. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130: 1194-205. (Pubitemid 47355941)
14. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Op Neurol. 2007; 20: 343-50. (Pubitemid 46743119)
15. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Op Neurol. 2007; 20: 255-60. (Pubitemid 46743105)
16. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125: 1450-61. (Pubitemid 34755161)
17. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 1224-34. (Pubitemid 47355951)
18. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med. 2006; 209: 269-75. (Pubitemid 43905560)
19. Takano R, Misu T, Takahashi T, et al. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008; 215: 55-9. (Pubitemid 351791268)
20. Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport. 2009; 20: 508-12.
21. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007; 69: 2221-31. (Pubitemid 350294677)
22. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aqauporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008; 205: 2473-81.
23. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008; 181: 5730-7.
24. Sabater L, Giralt A, Boronat A, et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol. 2009; 215: 31-5.
25. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med. 2006; 210: 307-13. (Pubitemid 44883971)
26. Waters P, Jarius S, Littleton E, et al. Aqauporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008; 65: 913-9. (Pubitemid 352008474)
27. Tani T, Sakimura K, Tsujita M, et al. Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J Neuroimmunol. 2009; 211: 110-3.
28. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66: 617-29.
29. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386: 623-7.
30. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenecity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66: 630-43.
31. Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology. 2009; 72: 1960-1.
32. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13: 128-32. (Pubitemid 46152772)
33. Zhou J, Kong H, Hua X, Xiao M, Ding J, Hu G. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport. 2008; 19: 1-5. (Pubitemid 351339611)
34. Klawiter EC, Alvarez E, Xu J, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 2009; 72: 1101-3.
35. Kim JH, Kim JH, Park JA, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol. 2006; 39: 339-45.
36. Tanaka M, Matsushita T, Tateishi T, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology. 2008; 71: 974-81.
37. Nicchia GP, Cogotzi L, Rossi A, et al. Expression of multiple AQP4 pools in the plasma membrane and their association with the dystrophin complex. J Neurochem. 2008; 105: 2156-65. (Pubitemid 351782248)
38. Aoki-Yoshino K, Uchihara T, Duyckaerts C, et al. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. Acta Neuropathol (Berl). 2005; 110: 281-8. (Pubitemid 41430657)
39. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988; 130: 443-54. (Pubitemid 18091372)
40. Warabi Y, Yagi K, Hayashi H, Matsumoto Y. Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is upregulated compared to multiple sclerosis. J Neurol Sci. 2006; 249: 145-52. (Pubitemid 44665918)
41. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 autoantibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev. 2009; 9: 132-5.
42. Matsushita T, Isobe N, Matsuoka T, et al. Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler. 2009; 15: 1113-7.
43. Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008; 4: 202-14. (Pubitemid 351516748)
44. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008; 65: 629-32. (Pubitemid 351679657)
45. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001; 49: 146-54. (Pubitemid 32157990)
46. Vural B, Chen L-C, Saip P, et al. Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer. 2005; 103: 2575-83.
47. Human Protein Atlas Web site. http://www.proteinatlas.org/. Accessed July 20, 2007.
48. Antoine JC, Camdessanche JP, Absi L, Lassabliere F, Feasson L. Devic disease and thymoma with anticentral nervous system and antithymus antibodies. Neurology. 2004; 62: 978-80. (Pubitemid 38435791)
49. De Santis G, Caniatti L, De Vito A, De Gennaro R, Granieri E, Tola MR. A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci. 2009; 30: 397-400.
50. Hu J, Verkman AS. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006; 20: 1892-4.
51. Hiroaki Y, Tani K, Kamegawa A, et al. Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol. 2006; 355: 628-39. (Pubitemid 41817624)
52. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-9. (Pubitemid 43958540)
53. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol. 2007; 254: 1233-7. (Pubitemid 350112363)
54. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008; 14: 1157-74.
55. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest. 2006; 116: 2393-402. (Pubitemid 44330138)
56. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009; 256: 1891-8.
57. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009; 73: 1628-37.
58. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent ON. Neurology. 2008; 70: 2197-200.
59. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59: 566-9. (Pubitemid 43358081)
60. Cabrera-Gomez J, Bonnan M, Gonzalez-Quevedo A, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler. 2009; 15: 828-33.
61. Marignier R, De Seze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler. 2008; 14: 440-5. (Pubitemid 351943855)
62. de Seze J, Arndt C, Jeanjean L, et al. Relapsing inflammatory ON: is it neuromyelitis optica. Neurology. 2008; 70: 2075-6.
63. Pittock SJ, Lennon VA, deSeeze J, et al. Neuromyelitis optica and non organ specific autoimmunity. Arch Neurol. 2008; 65: 78-83.
64. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009; 39: 87-90.
65. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009; 72: 712-7.
66. Hui AC, Wong RS, Ma R, Kay R. Recurrent optic neuromyelitis with multiple endocrinopathies: a new syndrome or just a coincidence? Mult Scler. 2006; 12: 670-3.
67. Kira J, Kawano Y. Recurrent optic neuromyelitis with endocrinopathies. Neurology. 1997; 49: 1475-6.
68. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement.Mult. Scler. 2005; 11: 617-21.
69. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003; 2: 117-27. (Pubitemid 37443332)
70. Das A, Puvanendran K. A retrospective review of patients with clinically definite multiple sclerosis. Ann Acad Med Singapore. 1998; 27: 204-9. (Pubitemid 128518749)
71. Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry. 2002; 73: 429-35.
72. Chopra JS, Radhakrishnan K, Sawhney BB, Pal SR, Banerjee AK. Multiple sclerosis in North-West India. Acta Neurol Scand. 1980; 62: 312-21. (Pubitemid 11241210)
73. Wu JS, Zhang JM, Carroll WM, Kermode AG. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry. 2008; 79: 1022-6.
74. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805-15. (Pubitemid 47238676)
75. Cabre P, Heinzlef O, Merle H, et al. Multiple sclerosis and neuromyelitis optica in Martinique. Neurology. 2001; 56: 507-14. (Pubitemid 32172877)
76. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain. 2002; 125: 2460-8. (Pubitemid 35303505)
77. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009; 256: 35-44.
78. Kuroiwa Y, Igata A, Itahara K, et al. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1084 cases. Neurology. 1975; 25: 845-51.
79. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53: 1107-14. (Pubitemid 29442132)
80. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60: 848-53. (Pubitemid 36297372)
81. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am. 2008; 18: 589-622.
82. Bichuetti D, Oliveira E, Souza N, Rivero R, Gabbai A. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler. 2009; 15: 613-9.
83. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007; 68: 603-5.
84. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996; 60: 382-7. (Pubitemid 26118744)
85. Rivera JF, Kurtzke JF, Booth VJ, Corona VT. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol. 2008; 255: 710-5.
86. de Seeze J, Stojkovic T, Ferriby D, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002; 197: 57-61. (Pubitemid 34462145)
87. Yamakawa K, Kuroda H, Fujihara K, et al. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology. 2000; 55: 318-20. (Pubitemid 30604647)
88. Braley T, Mikol DD. Neuromyelitis optica in a mother and daughter. Arch Neurol. 2007; 64: 1189-92. (Pubitemid 47258080)
89. Matiello M, Brum DG, Barreira A, Kingsbury D, Weinshenker B. Familial neuromyelitis optica. Neurology. 2008; 70: A266.
90. Cock H, Mandler R, Ahmed W, Sschapira AH. Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy. J Neurol Neurosurg Psychiatry. 1997; 62: 85-7. (Pubitemid 27047447)
91. Kalman B, Mandler RN. Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations, but polymorphisms also found in association with multiple sclerosis. Ann Neurol. 2002; 51: 661-2.
92. Celebisoy N, Akyurekli O, Copur A. Devic's neuromyelitis optica: a case with mitochondrial DNA mutations. Eur Neurol. 2006; 55: 93-5. (Pubitemid 43760321)
93. Ghezzi A, Baldini S, Zaffaroni M, et al. Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report. Neurol Sci. 2004; 25(Suppl 4): S380-2.
94. Hudson G, Mowbray C, Elson JL, et al. Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)? Brain. 2008; 131: e93.
95. Kim HJ, Park HY, Kim E, et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis. 2010; 37: 349-55.
96. Zephir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler. 2009; 15: 571-9.
97. Matsushita T, Matsuoka T, Isobe N, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens. 2009; 73: 171-6.
98. Yamasaki K, Horiuchi I, Minohara M, et al. HLADPB1* 0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999; 122: 1689-96. (Pubitemid 29425672)
99. Brum DG, Barreira AA, Santos AC, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler. 2010; 16: 21-9.
100. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008; 70: 344-52. (Pubitemid 351653396)
101. McKeon A, Lennon VA, Lotze S. CNS aquaporin-4 autoimmunity in children. Neurology. 2008; 71: 93-100.
102. Arabshahi B, Pollock AN, Sherry DD, Albert DA, Kreiger PA, Pessler F. Devic disease in a child with primary Sjögren syndrome. J Child Neurol. 2006; 21: 285-6. (Pubitemid 43891123)
103. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009; 286: 18-23.
104. Sellner J, Hemmer B, Mühlau M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmunity. 2009. doi:10.1016/j.jaut.2009.09.013
105. Vernant JC, Cabre P, Smadja D, et al. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology. 1997; 48: 58-64. (Pubitemid 27039518)
106. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007; 130: 1206-23. (Pubitemid 47355945)
107. Misu T, Fujihara K, Itoyama Y. Neuromyelitis optica and anti-aquaporin 4 antibody. An overview. Brain Nerve. 2008; 60: 527-37.
108. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006; 77: 1073-5. (Pubitemid 44338534)
109. Akman-Demir G, Eraksoy M, Tuzun E, et al. Devic's neuromyelitis optica: an analysis of 47 patients and prognostic implications of NMO IgG status. Neurology. 2008; 70(Suppl 1): A-267.
110. Adoni T, Lino AM, da Gama PD, et al. Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler. 2010; 16: 81-6.
111. Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long-term history and clinical predictors of death. J Neurol Neurosurg Psychiatry. 2009; 80: 1162-4.
112. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophtalmology. 2007; 114: 810-5.
113. de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008; 65: 920-3. (Pubitemid 352008475)
114. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009; 72: 1077-82.
115. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol. 2008; 255: 163-70.
116. Sellner J, Luthi N, Buhler R, et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 2008; 15: 398-405. (Pubitemid 351422397)
117. Sellner J, Luthi N, Schupbach WM, et al. Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging and laboratory findings. Spinal Cord. 2009; 47: 312-7.
118. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005; 65: 1479-82. (Pubitemid 41552787)
119. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute xacerbations. J Neurol Neurosurg Psychiatry. 2008; 79: 1075-8.
120. Blanc F, Zephir H, Lebrun C, et al. Cognitive functions in neuromyelitis optica. Arch Neurol. 2008; 65: 84-8.
121. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol. 2006; 13: 655-8. (Pubitemid 43873639)
122. Kim SM, Waters P, Vincent A, et al. Sjögren's syndrome myelopathy: spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromylitis optica. Mult Scler. 2009; 15: 1062-8.
123. Qiu W, Wu JS, Zhang MN, et al. Longitudinally extensive myelopathy in Caucasians: a West Astralian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry. 2010; 81: 209-12.
124. Filippi M, Rocca MA, Moiola L, et al. MRI magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology. 1999; 53: 1705-10. (Pubitemid 29530343)
125. Cordonnier C, deSeeze J, Breteau G, et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol. 2003; 250: 1447-52. (Pubitemid 38121841)
126. Cabrera-Gómez JA, Saiz-Hinarejos A, Graus F, et al. Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler. 2008; 14: 248-51. (Pubitemid 351639635)
127. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63: 390-6.
128. Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand. 2008; 118: 218-25.
129. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006; 63: 964-8. (Pubitemid 44036298)
130. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997; 17: 171-80. (Pubitemid 27008860)
131. Bichuetti DB, Rivero RL, Oliceira EM, et al. White matter spectroscopy in neuromyelitis optica: a case control study. J Neurol. 2008; 255: 1895-9.
132. Aboul-Enein F, Krssák M, Höftberger R, Prayer D, Kristoferitsch W. Diffuse white matter damage is absent in neuromyelitis optica. AJNR Am J Neuroradiol. 2010; 31: 76-9.
133. Johnson G, Miller DH, MacManus D, et al. STIR sequences in NMR imaging of the optic nerve. Neuroradiology. 1987; 29: 238-45. (Pubitemid 17077447)
134. Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain. 2002; 125: 812-22. (Pubitemid 34279776)
135. Matushita T, Isobe N, Matsuoka T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japan. Mult Scler. 2009; 15: 834-47.
136. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optico-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473-7. (Pubitemid 41186945)
137. Tortorella C, Ruggieri M, Zimatore GB, et al. Blood brain barrier impairment in NMO-IgG seropositive patients: an aquaporin-4 (AQP-4) related damage? Neurology. 2008; 70(Suppl 1): A268.
138. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007; 68: 1076-7. (Pubitemid 46569147)
139. Chan KH, Ramsden DB, Yu YL, et al. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol. 2009; 16: 310-6.
140. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J. 2008; 15: 99-105.
141. Fazio R, Malosio ML, Lampasona V, et al. Antiaquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler. 2009; 15: 1153-63.
142. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007; 4: e133.
143. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009; 66: 1134-8.
144. Smith CH, Waubant E, Langer-Gould A. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroopthalmol. 2009; 29: 104-6.
145. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010; 81: 109-11.
146. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006; 63: 1398-400. (Pubitemid 44547550)
147. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004; 63: 2363-70. (Pubitemid 40024351)
148. Milano E, Di Sapio A, Malucchi S, et al. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurol Sci. 2003; 24: 130-3. (Pubitemid 37304281)
149. Zaffaroni M. Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci. 2004; 25(Suppl 4): S368-70.
150. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502-17.
151. Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009; 256: 2082-4.
152. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009; 80: 575-7.
153. Jiang Y, Yang Y, Zhang B, Peng F, Bao J, Hu X. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett. 2009; 30: 85-90.
154. Bai S, Liu S, Guo X, et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Molecular Vision. 2009; 15: 1638-48.
155. Brinar VV, Habek M, Zadro I, et al. Current concepts in the diagnosis of transverse myelopathies. Clin Neurol Neurosurg. 2008; 110: 919-27.
156. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler. 2009; 15: 487-92.
157. Myers TD, Smith JR, Wertheim MS, et al. Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with MS. Br J Ophthalmol. 2004; 88: 673-80. (Pubitemid 38526652)
158. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007; 13: 256-9. (Pubitemid 46592781)
159. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with sever optic nerve and spinal cord demyelination. J Neurol Sci. 2007; 252: 57-61. (Pubitemid 44909191)
160. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008; 255: 305-7.
161. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009; 62: 167-70.
162. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008; 67: 195-205.
163. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999; 42: 1785-96.
164. Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008; 35: 172-4.
165. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46: 878-86.
166. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58: 143-6.
167. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004; 63: 1081-3. (Pubitemid 39287920)
168. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008; 10: 55-66. (Pubitemid 351176056)
169. Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004; 31: 265-7. (Pubitemid 38724824)
170. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51: 1219-20. (Pubitemid 28473439)
171. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65: 1443-8.
172. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270-2.
173. Bonnet F, Mercie P, Morlat P, et al. Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus. 1999; 8: 244-7. (Pubitemid 29186845)
174. Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008; 4: 381-6. (Pubitemid 351974010)
175. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006; 63: 957-63. (Pubitemid 44036296)
176. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007; 13: 968-74. (Pubitemid 351541430)
177. Minagar A, Sheremata WA. Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care. 2000; 2: 39-43.
178. Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford). 2006; 45: 913-5. (Pubitemid 43985386)
179. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromylitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66: 1128-33.